ONCODNA
7.4.2021 08:51:06 CEST | Business Wire | Press release
OncoDNA, a theranostic and genomic company specializing in precision medicine, and myNEO, an AI-driven company revolutionizing target identification within immuno-oncology, are thrilled to announce a new collaboration that will revolutionize cancer care. The two companies agreed to consolidate their core technologies to enable the production of personalized vaccines for patients who have run out of treatment options.
With the COVID-19, the field of mRNA therapeutics has been moving faster than ever before. In oncology, personalized vaccines can help fight cancer by selectively boosting the immune system. These vaccines can teach the body to recognize and eliminate tumor-specific neoantigens.
OncoDNA and myNEO will leverage their sequencing and bioinformatics technologies to identify and select the most effective neoantigens to target in a patient. While OncoDNA will perform whole genome and whole transcriptome sequencing, myNEO will handle the advanced interpretation of the sequenced data and design the optimal vaccine construct for maximum clinical benefit.
The project promises to guide patients through a completely personalized journey. The eligible patients would receive tailor-made vaccines as well as personalized follow-up by monitoring circulating tumor DNA after inoculation. With its OncoFOLLOW™ liquid biopsy, OncoDNA will help monitor the patient response and the evolution of the cancer very closely using personalized next-generation sequencing method.
“OncoDNA is delighted to jump with myNEO into this ambitious project. We stand at the forefront of innovation and the challenges ahead are herculean. Together we will work towards a world where patients with a hard-to-treat disease will have the opportunity to design their personalized elixirs. It may take years before this technology becomes a reality. However, the ongoing pilot tests on patients who do not respond to any therapy are showing promising results ”, commented Jean-Pol Detiffe, Chief Strategy & Innovation Officer and Founder of OncoDNA.
“Since day 1, myNEO’s mission has been to unlock the promise of immunotherapy via deep genomic and immune profiling of tumors,” described Cedric Bogaert, co-founder and CEO of myNEO. “Currently, our technology is used by biopharma partners to design the upcoming breakthrough immuno-oncology therapies. This project takes our ambition one step further in enabling OncoDNA’s vast network of clinicians and patients to directly benefit from this deep genomic and immune profiling. As such, this project holds great potential to make individualized immunotherapies more accessible to patients.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20210406006220/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates5.11.2026 12:00:00 CET | Press release
Total global revenues of $1.9 billion for the third quarter, an increase of 34% from the prior yearBRUKINSA (zanubrutinib) global revenues of $1.4 billion for the third quarter, an increase of 34% from the prior yearDiluted GAAP Earnings per American Depository Share (ADS) of $3.28 for the third quarter; non-GAAP diluted Earnings per ADS of $4.59 for the third quarterRaised 2026 total revenue guidance to $6.9 to $7.0 billion; GAAP operating income of $1.2 to $1.3 billion, non-GAAP operating income of $1.9 to $2.0 billion BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA, which drives powerful and sustained responses in pat
Sugar Taxes Under Scrutiny: New Competere Study Questions Health Outcomes and Warns of Unintended Consequences5.11.2026 12:00:00 CET | Press release
The science-based policy paper examines sugar taxes, warning labels, and reformulation, distinguishing changes in purchasing behavior from demonstrated health improvements and calling for smarter prevention. As governments debate sugar taxation and nutrition measures, a new policy paper asks a critical question: Do these interventions deliver lasting health improvements, for whom, and at what cost? Published by Competere with the support of the Association of Latin American Sugar Producers (UNALA), Understanding Sugar Beyond the Narrative – by Pietro Paganini – offers policymakers, journalists, and consumers an accessible guide to sugar’s role in health, sustainability, and the global economy. Combining scientific evidence with economic and policy analysis, the paper challenges common misconceptions and examines whether taxation, warning labels, and reformulation deliver measurable health benefits. While sugar taxes can influence prices, purchases, and product composition, evidence of
Klarna Goes Global With Anti-Scam Call Verification5.11.2026 11:52:00 CET | Press release
Klarna, the everyday finance network, today announced its popular in-app Call Status Detection tool is now live globally, giving consumers a reliable and simple way to check whether someone calling them is genuinely from Klarna. Call Status Detection has already helped thousands of consumers verify calls since it launched in the Nordics in September. The feature has now been rolled out globally, reflecting Klarna’s commitment to protecting its customers from fraud. Call Status Detection is quick and easy to use by design. If a customer takes a call from someone claiming to be Klarna, all they have to do is open the Klarna app and check the banner at the top of their screen — green means the call is verified and it is safe to continue, while amber means Klarna cannot verify the call and the customer should hang up. The feature builds on Klarna’s existing anti-fraud measures like the Klarna Inbox, which enables verification of written communication like emails, texts and letters, and aim
Prodalim Acquires South Africa’s Brenn-O-Kem, Expanding Its Global Circular Economy Platform with High-Value Grape-Based Specialty Ingredients5.11.2026 11:17:00 CET | Press release
Prodalim announced the acquisition of Brenn-O-Kem (BOK), a South African leader in upcycling winery by-products into high-value specialty ingredients for the wine, food and beverage, nutraceutical, agricultural and pharmaceutical industries. The acquisition strengthens Prodalim’s global circular economy platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103526127/en/ BOK transforms grape pomace and wine lees into a broad portfolio of natural, clean-label ingredients, including recycled aromatic alcohol for the wine and spirits industry; tartaric acid and derivatives for food, beverage and pharmaceutical applications; grape seed extracts for nutraceuticals; grape skin extracts for natural colors; grape seed oils and wine concentrates for culinary applications; and recycled compost for animal nutrition. Prodalim will acquire 93.25% of BOK for 37M USD. Founded in 1968, BOK operates three production sites in South Afric
SES Delivers Solid 9 Months & Q3 2026 Results and Reiterates Full-Year Outlook5.11.2026 10:22:00 CET | Press release
SES S.A. announces financial results for the nine and three months ended September 30, 2026. YTD 2026 Performance (€ million) YTD 2026 as reported (1) YTD 2025 as reported (1)(5) ∆ At constant FX (2) YTD 2025 like-for-like(3) ∆ At constant FX (2) Average €/$ FX rate 1.16 1.11 1.11 Revenue 2,472 1,743 +45.5% 2,628 -2.0% Adjusted EBITDA (4) 1,138 838 +40.0% 1,170 +1.4% 1) ‘Reported basis’ with Intelsat fully consolidated from July 17, 2025 2) ‘At constant FX’ refers to comparative figures restated at the current period FX rates to neutralize currency variations 3) ‘Like-for-like basis’ is as if Intelsat was fully consolidated from January 1, 2024 4) Excluding operating expenses/income recognized in relation to U.S. C-band repurposing, other income non-recurring, fair value movement on contingent value rights and other significant special items (disclosed separately) 5) 2025 has been restated to reflect Purchase Price Allocation (PPA) adjustments recorded in connection with the acquisitio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom